The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2010 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Kalorama Information has been closely following vaccine markets and has instituted a yearly market research report schedule since 2003 in order to keep up with fast-moving developments. Our latest comprehensive update, Vaccines 2011: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, examines the market for vaccines used in humans for various diseases. This state-of-the-industry report is a must-have for any executive who wants to stay on top of a rapidly changing market and see what’s expected down the road based on analysis of major company pipelines.
The report covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable.
Trends discussed in this report include the introduction of needle-free systems and the production of vaccines, as well as product safety, supply shortages, and the use of vaccines to prevent pandemics and address bioterrorism, DNA vaccinations, and innovations in vaccine delivery systems. News and reports of vaccine-related illness tend to exacerbate the public’s fears and result in higher rates of non-immunization, another issue which is discussed in this edition of the report.
Included in this report are current market size and forecast for the following vaccines:
Kalorama has expanded the global perspective of this report in this edition, including estimates of vaccine sales (pediatric and adult segments) in the following regions:
Revenue estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2014. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends... these form the basis of the forecasting and competitive analysis.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
In an industry facing patent expirations and layoffs, vaccine products continue to offer good news, according to healthcare market research publisher Kalorama Information. The world market for preventative vaccines totaled $25.3 billion in 2010, up from $22.1 billion in 2009, according to its annual report on the industry, Vaccines 2011: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. The report notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.3% during the next five years, as new product introductions continue and the products are sold to emerging markets.
"Vaccines are a priority at the major companies and there has been no let-up in the business in the four years that we have been tracking it annually," said Bruce Carlson, publisher of Kalorama Information. "We continue to see over nine percent growth in sales, and in some emerging markets the rate of growth is even faster. There is also a strong pipeline that should sustain growth as new products are launched."
The healthcare market research firm indicated that sales to Latin America, India and China will grow at double-digit rates.
Vaccines are commonly segmented into two target markets, adult and pediatric. According to Kalorama Information, the pediatric vaccine market is larger, accounting for more than half of the total market. Pediatric vaccines are also growing at a faster rate than adult vaccines and this is expected to continue over the next five years. Pneumococcal and "combination" DTaP vaccines continue to drive growth in the pediatric sector, while influenza and hepatitis vaccine products are driving sales in the adult segment of the market.
The world vaccines market is dominated by five major competitors: Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Together, they held four-fifths of the market in 2010. All but Pfizer and Merck posted strong double-digit growth in their vaccine businesses. Sanofi Pasteur, a subsidiary of Sanofi Aventis, was the leading manufacturer, according to Kalorama Information, with GlaxoSmithKline a close second. The company's position was largely due to its influenza products, although its polio/pertussis/Hib products also account for a significant portion of its vaccine sales.
More information is available from Kalorama Information's report, Vaccines 2011: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, including market forecasts, company profiles, and trends in the industry.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook